Celiac Disease (CD) - Market Insights, Epidemiology and Market Forecast 2025

  • ID: 4436375
  • Drug Pipelines
  • 130 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • BioLineRx Ltd
  • Celimmune
  • ImmunogenX
  • Immusant Inc.
  • Takeda Pharmaceuticals
  • MORE
Celiac Disease (CD) - Market Insights, Epidemiology and Market Forecast 2025 provides an overview of the Celiac Disease, epidemiology for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan and market trend of the Celiac Disease for the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Celiac Disease from 2015 to 2025 segmented by six major markets. In addition, The report also includes the forecasted epidemiology of Celiac Disease till 2025.The report also highlights the market drivers, market barriers and unmet medical need.

Our report provides the type specific prevalent, diagnosed and treatable population i.e. Gluten-free diet responsive CD and Refractory CD (along with RCD Type I and Type II). According to research, the prevalent population of Celiac Disease was estimated to be 4,027,782 in 2016. These are expected to grow for the study period i.e., 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Celiac disease was found to be very rare in Japan with negligible prevalence.

There is no approved drug for the treatment of Celiac disease. Gluten free diet (GFD) is the only approach to diminish the symptoms of CD. Expected launch of Larazotide Acetate (Innovate Biopharmaceuticals), Latiglutenase (ImmunogenX), Vedolizumab (Takeda), NexVax (ImmusanT) and AMG-714 (CelImmune) in forecast period shall have a huge impact on the otherwise stagnant market size of Celiac Disease.

United States contributes the major share of CD market as compared to EU5 countries and Japan. The therapeutic market of CD in 7MM is expected to be USD 59.0 Million in 2016. This is expected to increase for the study period i.e., 2015-2025.

Key Coverage and Benefits:
  • The report will help in developing business strategies by understanding the trends shaping and driving the global Celiac Disease market.
  • Organize sales and marketing efforts by identifying the best opportunities for Celiac Disease in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
  • The report provides historical as well as forecasted epidemiology of Celiac Disease in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
  • To understand the future market competition in the global Celiac Disease market and Insightful review of the key market drivers and barriers.
  • To understand the regulatory scenario in major markets.
The report also covers the detailed global historical and forecasted Celiac Disease market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) from 2015-2025.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • BioLineRx Ltd
  • Celimmune
  • ImmunogenX
  • Immusant Inc.
  • Takeda Pharmaceuticals
  • MORE
1. Report Introduction

2. Celiac Disease Market Overview at a Glance

3. Disease Background and Overview
3.1. Introduction
3.2. Types of Celiac Disease
3.3. Causes of Celiac Disease
3.4. Symptoms of Celiac Disease
3.5. Pathogenesis
3.6. Pathogenesis of RCD Type I:
3.7. Pathogenesis of RCD Type II:
3.8. Diagnosis
3.8.1. American college of Gastroenterology: Guidelines with Recommendations
3.8.2. British Society of Gastroenterology: Guidelines for the Diagnosis of Adult Coeliac Disease

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters

5. United States
5.1. Prevalent Cases of Celiac Disease in the United States
5.2. Diagnosed cases of Celiac Disease in the United States
5.3. Treatable Cases of Celiac Disease in the United States

6. Germany
6.1. Prevalent Cases of Celiac Disease in Germany
6.2. Diagnosed cases of Celiac Disease in Germany
6.3. Treatable Cases of Celiac Disease in Germany

7. France
7.1. Prevalent Cases of Celiac Disease in France
7.2. Diagnosed cases of Celiac Disease in France
7.3. Treatable Cases of Celiac Disease in France

8. Spain
8.1. Prevalent Cases of Celiac Disease in Spain
8.2. Diagnosed cases of Celiac Disease in Spain
8.3. Treatable Cases of Celiac Disease in Spain

9. Italy
9.1. Prevalent Cases of Celiac Disease in Italy
9.2. Diagnosed cases of Celiac Disease in Italy
9.3. Treatable Cases of Celiac Disease in Italy

10. United Kingdom
10.1. Prevalent Cases of Celiac Disease in the United Kingdom
10.2. Diagnosed cases of Celiac Disease in the UK
10.3. Treatable Cases of Celiac Disease in the UK

11. Japan
11.1. Prevalent Cases of Celiac Disease in Japan

12. Treatment of Celiac Disease
12.1. Treatment of Non-Responsive or Refractory Celiac Disease (RCD)
12.2. Therapy areas in Celiac Disease
12.3. American College of Gastroenterology: Guidelines with Recommendations for the management of Celiac Disease
12.4. British Society of Gastroenterology: Guidelines for the Management of Adult Coeliac Disease

13. Unmet needs

14. Key drugs in Development

15. Key Cross Competition

16. Emerging Drugs Chapters

17. Larazotide Acetate: Innovate Biopharmaceuticals
17.1. Regulatory Milestones
17.2. Other development activities
17.3. Clinical Development
17.4. Ongoing Trials Information
17.5. Safety and Efficacy
17.6. Advantages and Disadvantages
17.7. Product Profile

18. Latiglutenase (ALV003): ImmunogenX
18.1. Regulatory Milestones
18.2. Other development activities
18.3. Clinical Development
18.4. Ongoing Trials Information
18.5. Safety and Efficacy
18.6. Advantages and Disadvantages
18.7. Product Profile

19. AMG 714: Celimmune
19.1. Other development activities
19.2. Clinical Development
19.3. Ongoing Trials Information
19.4. Safety and Efficacy
19.5. Advantages and Disadvantages
19.6. Product Profile

20. Nexvax2: Immusant Inc.
20.1. Other development activities
20.2. Clinical Development
20.3. Ongoing Trials Information
20.4. Safety and Efficacy
20.5. Advantages and Disadvantages
20.6. Product Profile

21. BL-7010: BioLineRx Ltd
21.1. Other development activities
21.2. Clinical Development
21.3. Ongoing Trials Information
21.4. Safety and Efficacy
21.5. Advantages and Disadvantages
21.6. Product Profile

22. Vedolizumab: Takeda Pharmaceuticals
22.1. Clinical Development
22.2. Ongoing Trials Information
22.3. Product Profile

23. Celiac Disease: Market Analysis
23.1. Key Findings

24. Global Market Size of Celiac Disease
24.1. Total Market Size of Celiac Disease in 6MM by Therapies

25. United States
25.1. Total Market Size of Celiac Disease in US
25.2. Total Market Size of Celiac Disease in US by Therapies

26. EU5
26.1. Total Market Size of Celiac Disease in EU5
26.2. Total Market Size of Celiac Disease in EU5 by Therapies

27. Italy
27.1. Total Market Size of Celiac Disease in Italy
27.2. Total Market Size of Celiac Disease in Italy by Therapies

28. Germany
28.1. Total Market Size of Celiac Disease in Germany
28.2. Total Market Size of Celiac Disease in Germany by Therapies

29. France
29.1. Total Market Size of Celiac Disease
29.2. Total Market Size of Celiac Disease in France by Therapies

30. United Kingdom
30.1. Total Market Size of Celiac Disease
30.2. Total Market Size of Celiac Disease in United Kingdom by Therapies

31. Spain
31.1. Total Market Size of Celiac Disease
31.2. Total Market Size of Celiac Disease in Spain by Therapies

32. Japan Market Size

33. Market drivers

34. Market barriers

35. Appendix

36. Report Methodology
36.1. Sources Used

37. Consulting Services

38. Disclaimer

39. About

List of Tables
Table 1: Marsh classification of histologic findings in Celiac disease
Table 2: Recommendations for when to test for CD
Table 3: Recommendations for Diagnosis of CD
Table 4: Recommendations for Differentiation of CD from Non-Celiac Gluten Sensitivity
Table 5: Recommendations for Diagnosis of CD among Patients on a Gluten-Free Diet (GFD)
Table 6: Recommendations for Diagnosis of CD
Table 7: Prevalent Population of Celiac Disease in the United States (2015-2025)
Table 8: Diagnosed cases of Celiac Disease in the United States (2015-2025)
Table 9: Treatable cases of Celiac Disease in the United States (2015-2025)
Table 10: Prevalent Population of Celiac Disease in Germany (2015-2025)
Table 11: Diagnosed cases of Celiac Disease in Germany (2015-2025)
Table 12: Treatable cases of Celiac Disease in Germany (2015-2025)
Table 13: Prevalent Population of Celiac Disease in France (2015-2025)
Table 14: Diagnosed cases of Celiac Disease in France (2015-2025)
Table 15: Treatable cases of Celiac Disease in France (2015-2025)
Table 16: Prevalent Population of Celiac Disease in Spain (2015-2025)
Table 17: Diagnosed cases of Celiac Disease in Spain (2015-2025)
Table 18: Treatable cases of Celiac Disease in Spain (2015-2025)
Table 19: Prevalent Population with Celiac Disease in Italy (2015-2025)
Table 20: Diagnosed cases of Celiac Disease in Italy (2015-2025)
Table 21: Treatable cases of Celiac Disease in Italy (2015-2025)
Table 22: Prevalent Population of Celiac Disease in the United Kingdom (2015-2025)
Table 23: Diagnosed cases of Celiac Disease in the UK (2015-2025)
Table 24: Treatable cases of Celiac Disease in the UK (2015-2025)
Table 25: Fundamentals of gluten-free diet
Table 26: Medications used for Celiac Disease
Table 27: Recommendations for Management of CD
Table 28: Recommendations for Monitoring of CD
Table 29: Recommendations for Management of RCD
Table 30: Recommendations for Management of CD
Table 31: Key Drugs in Development
Table 32: Phase I/II drug analysis
Table 33: Total Market size of Celiac Disease in USD, Million (2015-2025)
Table 34: Total Market size of Celiac Disease in 6MM by Therapy (2015-2025)
Table 35: US Total Market Size of Celiac Disease in USD, Million (2015-2025)
Table 36: United States, Therapy Based Celiac Disease, Market Share (2015-2025)
Table 37: Total EU5 Market Size of Celiac Disease in USD, Million (2015-2025)
Table 38: Total EU5 Therapy Based Celiac Disease, Market Share (2015-2025)
Table 39: Italy Total Market Size of Celiac Disease in USD, Million (2015-2025)
Table 40: Italy Therapy Based Celiac Disease, Market Share (2015-2025)
Table 41: Germany Total Market Size of Celiac Disease in USD, Million (2015-2025)
Table 42: Germany Therapy Based Celiac Disease, Market Share (2015-2025)
Table 43: France Total Market Size of Celiac Disease in USD, Million (2015-2025)
Table 44: France Therapy Based Celiac Disease, Market Share (2015-2025)
Table 45: UK Total Market Size of Celiac Disease in USD, Million (2015-2025)
Table 46: UK Therapy Based Celiac Disease, Market Share (2015-2025)
Table 47: Spain Total Market Size of Celiac Disease in USD, Million (2015-2025)
Table 48: Spain Therapy Based Celiac Disease, Market Share (2015-2025)

List of Figures
Figure 1: Types of Celiac Disease
Figure 2: Mechanisms of mucosal damage in Celiac disease
Figure 3: High Producer of IFN? and Low Producer of Bach2
Figure 4: Gluten-dependent production of tissue transglutaminase 2 (TG2)-specific antibodies
Figure 5: Diagnosis of Celiac Disease
Figure 6: Prevalent Population of Celiac Disease in the United States (2015-2025)
Figure 7: Diagnosed Cases of Celiac Disease in the US (2015-2025)
Figure 8: Treatable Cases of Celiac Disease in the US (2015-2025)
Figure 9: Prevalent Population of Celiac Disease in Germany (2015-2025)
Figure 10: Diagnosed Cases of Celiac Disease in Germany (2015-2025)
Figure 11: Treatable Cases of Celiac Disease in Germany (2015-2025)
Figure 12: Prevalent Population of Celiac Disease in France (2015-2025)
Figure 13: Diagnosed Cases of Celiac Disease in France (2015-2025)
Figure 14: Treatable Cases of Celiac Disease in France (2015-2025)
Figure 15: Prevalent Population of Celiac Disease in Spain (2015-2025)
Figure 16: Diagnosed Cases of Celiac Disease in Spain (2015-2025)
Figure 17: Treatable Cases of Celiac Disease in Spain (2015-2025)
Figure 18: Prevalent Population with Celiac Disease in Italy (2015-2025)
Figure 19: Diagnosed Cases of Celiac Disease in Italy (2015-2025)
Figure 20: Treatable Cases of Celiac Disease in Italy (2015-2025)
Figure 21: Prevalent Population with Celiac Disease in the United Kingdom (2015-2025)
Figure 22: Diagnosed Cases of Celiac Disease in the UK (2015-2025)
Figure 23: Treatable Cases of Celiac Disease in the UK (2015-2025)
Figure 24: Therapy areas in Celiac Disease
Figure 25: Monitoring of Celiac Disease
Figure 26: Unmet needs for Celiac Disease
Figure 27: Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 28: Total Market size of Celiac Disease in 6MM by Therapies, USD Million (2015-2025)
Figure 29: United States Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 30: United States, Therapy Based Celiac Disease, Market Share (2015-2025)
Figure 31: EU5 Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 32: EU5, Therapy Based Celiac Disease, Market Share (2015-2025)
Figure 33: Italy Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 34: Italy, Therapy Based Celiac Disease, Market Share (2015-2025)
Figure 35: Germany Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 36: Germany, Therapy Based Celiac Disease, Market Share (2015-2025)
Figure 37: France Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 38: France, Therapy Based Celiac Disease, Market Share (2015-2025)
Figure 39: United Kingdom Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 40: United Kingdom, Therapy Based Celiac Disease, Market Share (2015-2025)
Figure 41: Spain Total Market Size of Celiac Disease in USD, Million (2015-2025)
Figure 42: Spain, Therapy Based Celiac Disease, Market Share (2015-2025)
Figure 43: Market drivers in Celiac Disease
Figure 44:Market barriers in Celiac Disease
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Takeda Pharmaceuticals
  • BioLineRx Ltd
  • Immusant Inc.
  • Celimmune
  • ImmunogenX
  • Innovate Biopharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll